MJIC, Inc. (“MJIC”) doing business as ManifestSeven, a fully integrated omnichannel platform for legal cannabis, announced that it received shareholder approval to consummate a merger with a wholly owned subsidiary of P&P Ventures, Inc. (TSXV:PPV.H) during its Annual Shareholders Meeting held on April 8, 2019.

P&P Ventures will be filing a listing application moving from the Toronto Venture Exchange (“TSXV”) to the Canadian Stock Exchange (“CSE”) and changing its name to ManifestSeven Holdings, Inc. (“M7”) with the requested trading symbol of MSVN. Upon completion of the Merger, all MJIC shareholders will become shareholders of M7 and the present business operations of MJIC will be wholly owned and continued by M7.

“We are pleased to embark on this important new stage in M7’s growth,” said Sturges Karban, Chief Executive Officer. “As M7 continues to build out a fully-compliant cannabis infrastructure across California, this transaction will enable the company to aggressively execute our long-term growth strategy and create value for all of our shareholders. We were overwhelmed by the shareholder turnout and support for the next phase of M7’s evolution.”

Haywood Securities, Inc., a leading Canadian independent investment bank, assisted in MJIC’s recent $15 million private placement announced in March 2019 and will continue as a financial advisor in connection with the merger and M7’s capital raising activities after its initial listing.

Prior to the execution of the agreement, M7 completed a private placement of 6,666,666 shares of common stock for aggregate gross proceeds of $15-million (U.S.) at an adjusted price of $2.25 (U.S.) (which is equivalent to 19,999,998 Class A shares upon exchange of such M7 securities for resulting issuer securities at an adjusted price of 75 U.S. cents per Class A shares).

The common shares of P&P Ventures were halted effective March 28, 2019 and are not expected to recommence trading on the TSX-V prior to delisting in connection with the completion of the proposed transaction. The proposed transaction is anticipated to close on or before June 30, 2019. The proposed transaction is an arm’s-length transaction.

On completion of the aforementioned shareholder meeting, M7 has elected a new board of directors and officers that will take the Company into completion of the transaction and listing on the CSE.

• Sturges Karban — President and Chief Executive Officer;

• Urban Smedeby — Executive Vice President;

• Jordan Gerber — Chief Financial Officer;

• Dmitry Gordeychev — Chief Investment Officer;

• Pierre Rouleau — Chief Operating Officer;

• Larry Horwitz — Corporate Secretary;

• Jarrod Smith — President of M7 Omnichannel;

• Daniel Sekers — Non-Executive Director and Chairman;

• Kristin Fox — Non-Executive Director;

• Scott Wessler — Non-Executive Director.


ManifestSeven (M7), formerly known as MJIC, is the first integrated omnichannel platform for legal cannabis, merging compliant distribution with a retail superhighway. The Company, based in Commerce, California, services the needs of lawful operators across the supply chain, from the cultivator to the consumer, through an expansive network of seven facilities stretching from the San Francisco Bay Area to San Diego. M7 further augments its business-to-business value proposition with a growing portfolio of owned and operated retail operations located in major metro markets, including brick-and-mortar dispensaries, local on-demand delivery services, e-commerce and subscription offerings. To learn more, please visit: www.manifest7.com.


Dave Quast, for ManifestSeven
+ 1 (213) 452-6348

Source: www.businesswire.com

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less